Studies on bladder cancer cell lines have shown that low adenoviral (Ad) infectivity is associated with low-level coxsackie adenovirus receptor (CAR) expression. Recently, we and others demonstrated a tumor stage-and grade-dependent downregulation of CAR expression in a large series of clinical bladder cancer specimens. Here, we demonstrate adenoviral gene transfer can be markedly enhanced in bladder cancer cells by upregulation of CAR through the use of certain differentiating agents, including the histone deacetylase inhibitors (HDACI) trichostatin A and sodium phenylbutyrate. CAR upregulation to supraphysiologic levels was demonstrated by quantitative rt-PCR, Western blotting, flow cytometry and adenoviral gene transfer. Normal urothelial cells and CAR-positive papilloma cells (RT4) failed to demonstrate upregulation under the same conditions. Upregulation was cell cycle dependent, associated with increased adenoviral gene transfer and persisted for at least 7 days after a single treatment. Such upregulation, however, appears to be tumor cell specific, as other CAR-negative cell lines failed to demonstrate enhanced adenoviral gene transfer with the same treatments. These results provide a rational basis for combining HDACI therapy with gene therapy as a method of augmenting activity in bladder cancer, but this strategy may not be universally applicable to other cell types.
W ith over 56,000 newly diagnosed cases each year and approximately 12,000 deaths in the United States, carcinoma of the bladder is the second most common cancer of the urogenital tract. 1 Although 70-80% of bladder tumors are superficial and can be treated by transurethral resection (TURB), these tumors recur 50-70% of the time and progress in about 20% of patients. 2 Treatment failures have limited alternative options and chemotherapeutic agents have proven long-term effectiveness in less than 20% of cases, with considerable toxicity. Thus, novel treatment methods are needed and adenoviral gene transfer may be able to circumvent resistance mechanisms in these treatment failures. 3 Adenoviral gene transfer requires the presence of both the coxsackie-adenovirus receptor (CAR) and certain patterns of integrin expression. CAR represents a highaffinity-binding site, which interacts with the knob domain of the adenoviral fiber protein present at each vertex of the icosahedral structure of the virus. 4 In addition to the CAR-fiber interaction, the virus also has a secondary interaction with certain patterns of integrins, in particular, a v /b 3 and a v /b 5 . 5 These adhesion molecules can interact with extracellular matrix ligands and are known to facilitate signal transduction. More recently, it was shown that heparan sulfate glycosaminoglycans can be receptors that mediate binding of adenovirus types 2 and 5. 6 In many bladder cancer cells, adenoviral gene transfer is impaired. Li et al reported that several human bladder cancer cell lines lacked expression of CAR, although the genomic sequences for the gene were intact. This downregulation correlated with resistance of urothelial cells to adenoviral infection. 7 More recently, Okegawa et al 8 showed a stage-dependent reduction of CAR mRNA level in clinical bladder cancer and described a growthinhibitory effect of CAR. We have also demonstrated a stage-and grade-dependent downregulation of CAR in clinical samples of bladder cancer by immunohistochemistry (IHC). 9 Although the precise physiologic role of CAR is unknown, it does have homology to certain cell-cell adhesion molecules and appears to complex to ZO-1 in the tight junctions of certain epithelial cells. 10 Loss of CAR expression correlates with increased growth and invasiveness, 8 and hence it may function as a tumor suppressor in certain malignancies.
CAR downregulation can be circumvented by retargeting adenovirus to receptors other than CAR for cell binding 11, 12 or by using bifunctional signaling antibodies to bypass the normal adenoviral receptors to improve gene delivery. 13 Here, we demonstrate that CAR downregulation is an epigenetic phenomenon, which can be reversed with histone deacetylase inhibitors (HDACI) in vitro in our bladder cancer cells. Importantly, normal urothelial cells or low-grade CAR-positive bladder cancer cells do not demonstrate induction of CAR expression under the same conditions. HDACI-induced CAR upregulation, however, is not universal as most glioma and osteosarcoma cell lines tested were relatively unaffected.
Materials and methods

Cell lines and tissue samples
T24 (anaplastic, invasive bladder cancer cell line), 14 RT4 (human, bladder papilloma cell line), 15 TCC-SUP (human, invasive bladder cancer cell line), 16 HT1376 (human, invasive bladder cancer cell line) 17 and HEK293 cells (human embryo kidney, a packaging cell line for adenovirus, which is known to express very high levels of CAR) were purchased from American Tissue Culture Collection (Manassas, VA). RT4 and T24 cells were grown in McCoy's 5A medium (Mediatech Inc., Herndon, VA) and HT1376, TCC-SUP and 293 cell lines were grown in Dulbecco's modification of Eagle's medium (Mediatech Inc.). All cell lines were supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamicin. Primary urothelial cultures were obtained from the bladders of normal pediatric patients undergoing surgery for ureteral reimplantation, under a protocol approved by our institutional review board. Cells were harvested directly into RPMI-1640 with 10% FBS, and then CAR-positive urothelial cells were separated from the smooth muscle cells and fibroblasts (both of which are CAR negative) by flow cytometry with the anti-CAR antibody RmcB (obtained from ATCC, Catalog Number CRL-2379, Manasas, VA). Human osteosarcoma cell lines MG-63, SaOs-2, MNNG-HOS and CAL-72 were also used. MG-63 was obtained from Dr Clemens-Lowik (Leiden University Medical Center); MNNG-HOS and SaOs-2, courtesy of Dr F van Valen (Westfa¨lische Wilhelms-Universitat Mu¨nster) and CAL-72 courtesy of Dr J Gioanni (Laboratoire de Cancerologie, Faculte de Medicine, Nice), as described previously. 18, 19 Human glioma cell lines were used including VU1.2 (obtained from a glioma patient, VU-University Amsterdam), U118, U373 and IGRG-121 (all CAR negative, except U373) as described before. 20, 21 For CAR upregulation studies, either 5-aza-2 0 -deoxycytidine (5-aza-2-CdR) (Sigma, St Louis, MO), trichostatin A (TSA) (Sigma) or sodium phenylbutyrate (NaPheBt) (Triple Crown America, Inc., Perkasie, PA) were added to the growth medium. Cell confluence at the time of analysis was 90-95%. RmcB (CRL-2379) for production of the murine monoclonal CAR antibody was purchased from American Type Culture Collection (ATCC, Rockville, MD) and sent to Harlan Bioproducts (Madison, WI) for ascites production. Snap-frozen specimens of normal urothelium (n ¼ 3) were obtained for quantitative rt-PCR analysis.
Real-time quantitative reverse transcriptase polymerase chain reaction for CAR Quantitative real-time reverse transcriptase polymerase chain reaction (rtPCR) was carried out as previously described. 9 The sense and antisense primer sequences for CAR were 5 0 TTGCTTGCTCTAGCGCTCATTGGTC 3 0 and 3 0 TCATCACAGGAATCGCACCCATTCG 5 0 , respectively. Amounts of target DNA (relative CAR copy number per haploid) were quantified using the following equation:
Relative CAR copy number per haploid genome ¼ CAR copy number b Actin copy number
The CAR copy number was calculated by generating a standard curve based on the amplification of known amounts of a plasmid carrying the CAR sequence. RNA values were then normalized by amplifying the constitutively expressed housekeeping gene b-actin.
CAR Upregulation in T24 cells
T24 cells were treated with 5-aza-CdR (10 mM, 48 hours), a cytidine analog with a nitrogen atom in the 5 0 position of the pyrimidine ring, which is incorporated into RNA and DNA and which cannot be methylated. Furthermore, it is known that 5-aza-CdR inhibits the DNA-cytosine methyltransferase and therefore inhibits inactivation of certain gene promoters. Cells were also treated with the histone deacetylase inhibitors TSA (50 or 500 ng/ml, 48 hours) and NaPheBt (5 mm, 72 hours) prior to realtime quantitative rt-PCR, Western blotting, flow cytometry and adenoviral binding studies.
Western blot for CAR expression
T24 cells were treated with either TSA, or NaPheBt as detailed in the legend of Figure 2 , for a total of 3 days prior to harvesting for western blot analysis. The timing of this analysis was based on flow cytometry data (Fig 4) that demonstrated maximal induction of CAR occurs by day 3. Cell extracts from T24, T24 þ TSA, T24 þ NaPheBt and 293 cells were homogenized in a lysis buffer containing 0.5% Triton X-100 (Sigma), homogenates were centrifuged and the supernatants were collected. Protein concentration was determined using a commercial Bradford assay (Bio-Rad). Protein extracts were boiled for 5 minutes in Laemmli sample buffer (BioRad), electrophoresed on a 10% Tris-HCl ready gel (BioRad) and transferred to a polyvinylidene difluoride membrane (Bio-Rad) using a semidry Trans blot system (Bio-Rad). Immunoblotting was performed using the RmcB (CRL-2379, ATCC, Manassas, VA) monoclonal antibody, which is known to recognize denatured CAR protein 4 and the ECL Western blotting detection system and protocol (Amersham, Piscataway, NJ).
Flow cytometry for CAR expression
T24 and 293 cells were treated with NaPheBt (5 mM, 72 hours), or TSA (500 ng/ml, 48 hours), harvested (10 6 cells/ml) and analyzed by flow cytometry. In one set of experiments, we synchronized the cells to the same phase of the cell cycle by withdrawing serum from the media for16 hours prior to harvesting and then performing flow cytometry. The harvested cells were incubated with a 1:1000 dilution of the RmcB monoclonal CARantibody or with the integrin a v antibody MAB 1958 (Chemicon, Temecula, CA) in a single cell suspension for 60 minutes at 41C. Cells were then washed with PBS containing 2% FBS and treated with R-Phycoerythrin (R-PE)-conjugated rat anti-mouse IgG1 monoclonal antibody (BD PharMingen, San Diego, CA) for 30 minutes at 41C. Finally, the cell suspension was washed and fixed with 1% paraformaldehyde. Fluorescence analysis was performed by fluorescence activated cell analysis (FACSCalibur, Beckton Dickenson, San Jose, CA) at the Johns Hopkins Flow Cytometry core facility. Determination of the positive cell population was carried out by gating the right-hand tail of the negative control (secondary antibody only) for each cell line at 1% and applying this setting to each sample acquisition.
Adenovirus gene transfer of luciferase gene
T24 cells (10 4 ) were treated with either TSA (50 ng/ml, 48 hours at 371C) or NaPheBt (5 mM, 72 hours at 371C) and incubated for 45 minutes. with increasing quantities (0, 10, 20, 50 or 100 multiplicities of infection (MOIs)) of luciferase transgene carrying adenovirus AdL (no modification), AdLPB(HA)b(HA) (penton base-ablated), AdL.F(REAK-HA) (fiber-ablated), or AdL.PB(HA)-F(REAK-HA) (fiber-and penton base-ablated), or AdZ.F(RGD) (fiber modified to include RGD in HI loop) (GenVec, Gaithersburg, MD). [22] [23] [24] [25] These data are presented in Figures 5 and 6 . In an additional experiment AdL (no modification), AdLPB(HA)b(HA) (penton baseablated), AdL.F(REAK-HA) (fiber-ablated), or Ad-L.PB(HA)F(REAK-HA) (fiber-and penton base-ablated) were used at a concentration of 10,000 Pu/cell and incubated for 3 hours. For blocking assays, T24 cells were incubated with increasing quantities (1.25, 2.5 and 5 mg/ ml) of soluble fiber protein (GenVec) for 1 hour at 371C prior to adenovirus infection. Assuming roughly 15,000 CAR receptors per cell (based on previously published data 26 ), we estimate a 10,000-fold molar excess of soluble fiber in the 5 mg/ml experiment.
In the last experiment (Fig 8) bladder cell lines (primary urothelium, RT4, T24, TCC-SUP and HT1376), osteosarcoma (MG-63, SaOs-2, MNNG-HOS and CAL-72 ) and glioma (VU1.2, U118, U373 and IGRG-121) cell lines were treated with 50 ng/ml of TSA for 48 hours prior to infection with AdL at MOIs of 50 PFU/cell for the osteosarcoma and glioma cell lines and at an MOI of 25 PFU/cell for the urothelial cell lines. All experiments were performed in triplicate. Adenovirus transduction rates were measured using a luciferase reporter gene assay (Roche) and the 1450 Microbeta Luminometer (Wallac, Turku, Finland). Data were normalized to total cell number using the MTT-assay and protocol (Trevigen, Gaithersburg, MD).
Statistical Handling of Data
All experiments were performed in triplicate or quadruplicate and replicated on at least one occasion. Error bars plotted represents the average 7 the standard error of the mean (SEM). Statistical significance was assessed by the Student's t-test, using an IBM compatible computer running Microsoft Excel on the Windows-XP operating system. All P-values less than 0.05 were considered significant.
Results
Upregulation of CAR expression
The CAR promoter has a CpG island just upstream of exon 1. Hence we reasoned that the low expression of this gene might be a consequence of promoter hypermethylation. We therefore sought to determine if upregulation could be achieved by administration of an agent known to reverse DNA hypermethylation in vitro, 5-aza-2'-deoxycytidine (5-aza-2-CdR). Treatment with 5-aza-2-CdR resulted in minimal reactivation of CAR expression (Fig 1) as measured by real-time quantitative rt-PCR analysis. In contrast, treatment of T24 cells with sodium phenylbutyrate (NaPheBt) induced a 21.8-fold increase, 2.0-fold higher than in clinical normal bladder specimens. Treatment with TSA induced a 31.6-fold increase in CAR-expression, 3.0-fold higher than in clinical normal bladder specimens (Fig 1) . AlThough there is evidence for synergistic activity between hyperacetylating drugs and demethylation agents, 27 in our experiments combining 5-aza-2-CdR with either TSA or NaPheBt resulted in an intermediate upregulation between 5-aza-2-CdR alone and either HDACI alone (data not shown). Such data would suggest that the CAR promoter is not densely methylated in these cells, consistent with recent observations of the CAR promoter function. 28 Western blot analysis of T24 cells confirmed increased CAR protein production after treatment with NaPheBt or TSA (Fig 2) . Untreated T24 cells had undetectable CAR protein levels, while NaPheBt and TSA treated T24 cells displayed CAR expression levels similar to those seen in our positive control, 293 cells. Additionally, the pattern of CAR reactivation correlates between quantitative rt-PCR and Western analysis. Higher expression was obtained with TSA exposure as compared to NaPheBt treatment.
Low expression of CAR in the T24 cell line was confirmed by flow cytometry, where only approximately 3-6% of the cells demonstrated a signal shift compared to the unstained control. By contrast, this shift was raised up to 18% of NaPheBt and 40% of TSA-treated T24 cells (Fig 3a) , again consistent with our real-time quantitative rt-PCR and Western blot data. After cell-cycle synchronization by serum starvation, the number of CARexpressing cells increased from 22% (untreated) to 50 and 83% after NaPheBt and TSA treatment respectively (Fig 3b) .
Upregulation after NaPheBt treatment in unphased cells was found to be present for at least 7 days (Fig 4) after the treatment. Flow cytometry experiments showed no increase in a v integrin levels after HDACI treatment (data not shown), although we have previously demonstrated that a v integrin is already highly expressed in invasive bladder cancers and therefore additional increases would not be readily evident by this method. 9 
Adenoviral gene transfer assays
We assessed adenoviral gene transduction rates in T24 cells that were treated with HDACI, which confirm the previously reported resistance of T24 cells to adenoviral infection (Fig 5a-c) . 7 Treatment with NaPheBt or TSA leads to markedly increased transduction by adenovirus. Increased transgene expression can result from multiple mechanisms, including increased CAR expression, increased a v integrin expression, increased protein synthesis or decreased protein degradation. In order to better distinguish between these possibilities, we studied the transgene expression of luciferase in the following adenoviral mutants: AdL (no modification), Ad-LPB(HA)b(HA) (penton base-ablated, which disrupts integrin binding), AdL.F(REAK-HA) (fiber-ablated, which disrupts CAR binding), or AdL.PB(HA)-F(REAK-HA) (fiber-and penton base-ablated, which disrupts both CAR and integrin binding) adenoviral vectors. Transduction rates were lower after infection with the penton base-ablated (AdLPB(HA)b(HA), Figure 5b ), and the fiber-ablated (AdL.F(REAK-HA), Figure 5c ). Gene transfer for the double-ablated vector (AdL.PB(HA)F(REAK-HA)) was undetectable (data not shown), suggesting that adenoviral infection requires either fiber-CAR or penton base-integrin interactions. In an additional experiment (Table 1) , we tested how much of the increase in transgene expression is really due to CAR-upregulation versus other mechanisms. In order to accomplish this fold comparison, we needed to increase the level of transgene expression in the ablated vectors into the clearly measurable range. Therefore, we choose extreme infection conditions and incubated the cells at an MOI of 10,000 for 3 hours with the four different adenoviruses. In this way, we achieved measurable luciferase activity even in the untreated T24 cells, which then served as a baseline for calculating the fold induction by TSA treatment. For the wild-type vector, a 43-fold induction was achieved after treatment with TSA. In contrast, luciferase activity was not increased after treatment in the case of the CAR-or double-ablated vectors. Interestingly, a 175-fold induction of luciferase activity was achieved after treatment with TSA in the integrin-ablated vector, consistent with CAR expression being the dominant mechanism for enhanced gene transfer. The higher fold induction in this case was most likely a result of loss of integrin-mediated uptake in the untreated T24 cells (ie, a lowered denominator led to a higher fold increase). If the primary determinant of HDACI-induced activation of adenoviral transgene expression is CAR mediated, then we predicted that an integrin-redirected, double-ablated vector would demonstrate no difference in transgene expression after HDACI treatment. Thus, we took the RGD-redirected adenoviral vector (AdZ.F(RGD)) 25 and performed infections in a panel of five bladder lines, including the invasive bladder lines T24, HT1376, TCC-SUP, the benign bladder papilloma RT4 and normal primary urothelium (see Figure 6 ). As expected, binding to all the cell lines was high regardless of treatment with TSA, as the virus was able to enter the cell through binding of the a V integrins. In only one of the five cell lines (HT1376) was there a measurable difference in transgene expression after TSA treatment, however, even in this cell line the difference in expression barely reaches statistical significance (P ¼ .045). These results are consistent with upregulation of CAR being the major mechanism of enhanced adenoviral gene transfer by HDACI.
In a separate experiment utilizing wild-type adenovirus fiber (i.e., CAR dependent), we tested the necessity of CAR binding by performing competition experiments with soluble fiber. When soluble fiber was added to the incubation mixture, we were able to decrease the luciferase expression of the wild-type adenoviral vector up to 56 and 69% for TSA-and NaPheBt-induced infection, respectively (Fig 7) . Again, a decrease of CAR binding resulted in a decrease in transgene expression, although the inhibition was incomplete. The inability to inhibit completely adenoviral gene transfer with a gross molar excess of soluble fiber suggests that part of the HDACI-induced augmentation of reporter gene expression is mediated through non-CAR-mediated pathways (e.g., enhanced transcription, or protein stabilization).
In order to determine whether HDACI-mediated enhanced adenoviral gene transfer was a more general phenomenon, we evaluated a panel of CAR-negative bladder cancers, glioma and osteosarcoma cell lines for increasing transgene activity after TSA treatment (Fig 8a-d) . Of the eight nonbladder cancer cell lines, only one glioma (U373) and one osteosarcoma (MG-63) demonstrated enhanced adenoviral gene transfer after TSA treatment. It should be noted that while the osteosarcoma line did have a statistically significant induction of transgene expression, the overall infectivity and luciferase expression was still nominal compared to all other cell lines. The U373 cell line has a low but measurable CAR expression and demonstrated a marked enhancement of adenoviral gene transfer with TSA treatment. In contrast, Figure 4 Evaluation of the duration of CAR upregulation. T24 cells were treated with NaPheBt and evaluated for CAR expression as a function of time. As can be seen, the upregulation of CAR lasted for at least 7 days after prior treatment with an HDACI. all three CAR-negative invasive bladder cancer cell lines (T24, TCC-SUP and HT1376) demonstrated enhancement of gene transfer with TSA treatment. As controls, two strongly CAR-positive cells were also tested for enhanced gene transfer after TSA treatment (RT4 a bladder papilloma cell lines, and Urothelial, which are normal urothelium primary cultures). It should be noted that the normal urothelium cells had a baseline luciferase expression at least 3 logs higher than any of the transformed cell lines analyzed, including the RT4 papilloma cells. Both of the CAR-positive bladder controls demonstrated no significant induction.
Discussion
Preclinical models of bladder cancer gene therapy have demonstrated an unusually high requirement for adenoviral vectors. 29 Analysis of bladder cancer cell lines has demonstrated the cause of this resistance to adenoviral gene transfer to be a marked downregulation of CAR expression. 7 In order to determine whether this expression pattern was an artefact of tissue culture, CAR expression in clinical bladder cancer samples has been extensively analyzed. This evaluation has been performed at the level of mRNA expression, showing an apparent downregulation only in invasive tumors, 8 as well as at the protein level by IHC also demonstrating a stage-and gradedependent downregulation in CAR expression. 9 One of the best studied invasive bladder cancer cell lines (T24) is CAR-negative, but the genomic sequences for CAR are neither deleted nor mutated. Hence, we reasoned that epigenetic regulation led to silencing of gene expression, a process that might be reversed by use of certain histone deacetylase inhibitors. Our results demonstrate that CAR expression can indeed be upregulated to supraphysiological levels after treatment with HDACIs. To determine if the upregulated CAR protein was functional, we examined adenoviral transduction rates in T24 cells that were A total of 10 4 cells were plated in triplicates and treated with TSA (50 ng/ml, 48 hours at 371C). In contrast to previous experiments, cells were strongly overinfected by incubating with the four viruses at an MOI of 10,000 for 3 hours. The luciferase activity was measured after an overnight incubation at 371C and the fold induction of TSA treatment compared to untreated cells was calculated. These high MOIs were necessary in order to get a measurable background luciferase expression with the CAR-or integrin-ablated vectors and in the CAR-negative cells. The TSA treatment lead to a 43-and 175-fold induction after infection with the wild-type and the integrin-ablated vectors, respectively. In contrast, luciferase activity was not increased after treatment in the CAR-or double-ablated vectors. Figure 6 Evaluation of transgene expression of AdZ.F(RGD) (CARablated, penton base-ablated, retargeted to a V integrin). A doubleablated vector, which has been retargeted a V integrin by incorporation of an RGD motif in HI loop of the fiber knob was used to assess changes in gene transfer before and after TSA treatment (50 ng/ml, 72 hours, 371C). This highly engineered virus can only enter cells by binding to the á V integrin through the fiber knob. Cell lines tested included the bladder cancer cells T24, RT4, TCC-SUP, HT1376 and normal primary urothelium (labeled Urothelial). As predicted, TSA treatment does not cause a noticeable change in transgene expression since CAR binding has been circumvented. Figure 7 Blocking of adenoviral attachment by soluble fiber. In total, 10 4 cells were plated in triplicates and treated with either TSA (48 hours at 371C) or NaPheBt (72 hours at 371C). Cells were incubated with increasing quantities of soluble fiber protein at 371C for 1 hour prior to infection with 100 MOI adenovirus carrying the luciferase transgene. A decrease of up to 69 and 56% luciferase activity could be shown for NaPheBt and TSA treated cells, respectively, indicating the importance of CAR for transgene expression. Error bars indicate standard errors of the mean.
exposed to NaPheBt or TSA. We confirmed the previously reported result that T24 cells are resistant to adenoviral infection. 7 Treatment with NaPheBt or TSA correlated with increased transduction by adenovirus, as shown in Figure 5a . Previous findings show that TSA and butyrate analogs increase adenoviral transgene expression 30 in HeLa and A549 cells. However, it has only recently been determined that such agents enhance adenoviral transgene expression by increasing expression of CAR. 31, 32 In the case of bladder cancer, the relationship of CAR expression to histologic changes has been firmly established. [7] [8] [9] High-grade invasive bladder cancers are downregulated in CAR expression, while low-grade tumors (e.g., papillomas) have a normal CAR expression pattern. We tested whether or not HDACIs could trigger re-expression of CAR, and whether or not this reexpression was solely responsible for the enhancement of adenoviral gene transfer. Transfection studies with adenoviral mutants showed that both CAR and a v integrin binding are essential for optimum adenoviral gene transfer. A minor level of transduction was observed, however, after using very high concentrations of the vectors (Fig 5b, c) , presumably through nonspecific binding and uptake. Under these extreme infection conditions, only the wild-type and integrin-ablated vectors demonstrated a significant induction after treatment with TSA. We interpret this finding as evidence that HDACI induction of CAR expression is the major mechanism for increased transgene expression. In the case of the integrin-ablated vector, the untreated T24 cells lacked CAR expression and the integrin-ablated vector lacked the ability to bind and internalize via the RGDbinding motif. Hence, this experiment functionally abolished both major pathways of binding and internalization. After induction of CAR with TSA, however, the fold induction was markedly enhanced because now a major pathway for cellular entry was reconstituted (CARmediated, without integrin internalization). These findings highlight the necessity for high-level CAR expression in order to achieve enhanced gene transfer. However, they do not exclude additional mechanisms from contributing to the enhanced gene transfer effect. In a separate experiment, we utilized an integrin-retargeted adenoviral vector AdZ(RGD), which has been ablated for the normal binding and uptake mechanisms (double-ablated, fiber and penton base) and retargeted to alpha V integrin by placing the RGD-targeting ligand in the HI loop of the fiber knob. If CAR expression were the sole mechanism for causing upregulation of adenoviral transgene expression, then we would predict that changes in CAR expression would have no effect on this particular vector -as the CAR pathway has been ablated. As predicted, TSA treatment of the various bladder cancer cell lines resulted in only marginal changes in transgene expression (Fig 6) , and was only marginally statistically significant in one of the cell lines (HT1376, P ¼ .045).
As a separate test for the role of CAR in regulating HDACI-induced adenoviral transgene expression, we performed competition experiments with a gross molar excess of soluble fiber. The fact that we were able to demonstrate competition of the HDACI-induced enhanced gene transfer effect through the use of soluble fiber further confirms our observations that CAR upregulation plays the major role in enhancing transgene expression. However, additional non-CAR mechanisms (e.g., enhanced transcription or protein stablization) do appear to also play a minor role in stimulating enhanced gene transfer activity, as the competition experiments were unable to eliminate the enhancement effect completely, even in gross molar excess.
Low CAR expression has been found in a variety of tumors making them inaccessable for adenoviral gene therapy. Such findings have been described for bladder cancer, 9 prostate cancer, 33 ovarian cancer, 34 renal cancer, 11 osteosarcomas 19 and gliomas 21 among others. In the case of bladder cancer, these low levels of CAR have been documented in clinical specimens by RNA and protein, and may reflect a part of the pathophysiology of bladder cancer invasiveness, as CAR expression seems to correlate inversely with stage and grade. 8, 9 Our results demonstrate however, that while HDACIs are capable of upregulating CAR expression in all of the invasive bladder cancer cells tested, this approach is not generally applicable to all tumors. Equally important is the fact that HDACI treatment does not increase CAR expression in those bladder cells that already have normal expression (e.g., primary urothelial cells and papilloma). The net result is that such treatments should result in preferential sensitization of bladder cancer cells to adenoviral gene therapy, without increasing the background nontarget binding to normal urothelial cells. Such an effect would be particularly advantageous in targeting cancer cells for adenoviral gene transfer in heterotopic and orthotopic models of bladder cancer, as well as potential clinical trials of adenoviral gene therapy for bladder cancer. It should be emphasized that the experiments presented here were performed completely in vitro and caution should be employed when extrapolating these results to in vivo situations.
Bladder cancer presents unique issues with regards to adenoviral gene therapy. The so-called glycosaminoglycan layer (GAG) of the bladder urothelium represents a significant barrier to any potential orthotopic gene therapy. 35, 36 In addition, high-stage and high-grade bladder cancers often lack expression of the receptor for adenoviruses. 9 Recently, significant efforts have been made to overcome some of the barrier problems of the native bladder to efficient gene transfer, including the addition of detergents. To date, the most effective method of overcoming the GAG barrier has been the use of a polyamide detergent called Syn3. 37 This agent appears to facilitate gene transfer regardless of CAR status and may be quite useful for native bladder applications. However, as a topical agent, it does not address the more fundamental issue of enhancing gene transfer in cancer cells embedded deep within muscle tissue, in locally advanced disease, or even in remote metastatic disease. In order to approach these more difficult sites with adenoviral gene transfer, a method must be developed that enhances the gene transfer efficiency, particularly in the CAR-negative malignancies. We describe a potential strategy for enhancing adenoviral gene transfer into invasive bladder cancer cells, based on the use of HDACIs. Given the growing list of clinically applicable HDACIs (e.g., suberoylanilide hydroxamic acid (SAHA), or valproic acid), we believe these studies provide a good rationale for the evaluation of such agents as a neoadjuvant to adenoviral gene therapy.
In summary, CAR expression can be upregulated using certain HDACIs in CAR-negative bladder cancer cell lines. This increase is evident by mRNA, protein expression and by functional analyses of gene-transfer efficiency. This increase in CAR expression persists for at least a week after a single treatment and appears to be cell cycle dependent. Competition experiments with soluble fiber and transfection assays demonstrate that CAR upregulation is the major mechanism of enhanced transgene expression. These overall effects may prove ultimately useful in the clinical applications of HDACIs to adenoviral gene therapy, but may not be universally applicable to all tumor types.
